Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.34 which represents a slight increase of $0.03 or 2.29% from the prior close of $1.31. The stock opened at $1.32 and touched ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...
Editas Medicine (NASDAQ: EDIT) recently received a number of ratings updates from brokerages and research firms: 12/16/2024 – ...
19d
Hosted on MSNEDIT Stock Falls on Decision to End Reni-Cel Studies, Cut WorkforceShares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its ...
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
Dec 12 (Reuters) - Editas Medicine (EDIT.O), opens new tab said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's ...
Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.
Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a ...
Baird lowered the firm’s price target on Editas Medicine (EDIT) to $8 from $10 and keeps an Outperform rating on the shares. The firm said they expect the shares could move higher as the in vivo ...
Editas Medicine Inc.股价跌至52周新低,触及1.27美元,较52周高点11.58美元大幅下跌89%。这家生物科技公司目前市值仅为1.06亿美元,尽管其资产负债表健康,现金多于债务,但仍面临市场逆风。这一最新价格较之前的估值显著下降,反映出过去一年88%的急剧下跌。投资者对公司前景持谨慎态度,导致持续抛售,最终达到这一新低。根据 InvestingPro ...
In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results